WCG will encourage members of its Global Research Network (GRN) to accept the Accelerated Clinical Trial Agreement (ACTA) as their default agreement for industry-sponsored, multi-center clinical trials. “All of WCG’s solutions help our clients to reduce the time, cost and risks associated with bringing new therapies to market,” said Donald A. Deieso, Ph.D., chairman and CEO of WCG. “The clinical trial process is plagued with administrative inefficiencies and unnecessary delays. We are proud to promote the hard work of the CTSAs and the UIDP, and to encourage our clients to adopt the ACTA.”

News coverage of this announcement is highlighted below:

Publication: Applied Clinical Trials
To read this article, please click here

Publication: BioPortfolio
To read this article, please click here

Publication: Clinical Informatics News
To read this article, please click here

Publication: MS Dreams
To read this article, please click here

Publication: PHARMABIZ.com
To read this article, please click here

Publication: PharmaVOICE
To read this article, please click here

Print Friendly